• News
  • SAN DIEGO
  • BioTech

Allergan Board Turns Down Valeant’s Latest $54 Billion Bid

June 10 (Bloomberg) -- Allergan Inc.’s board rejected the latest offer by Valeant Pharmaceuticals International Inc. and investor Bill Ackman, calling it undervalued.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!